Carl Zeiss Meditec Ag (CZMWF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and a warm welcome to today's earnings call of the Carl Zeiss Meditech Group, following the publication of the six-month figures of 2025-2026. And with this, I hand over to the head of Group Finance and Investor Relations, Sebastian Frerichs. Hello, good morning, everybody, and thank you for joining our six-month 2025-2026 earnings call. As usual, our management will guide you through our financials, and then we will talk quite a bit today about our ProfitUp program, including the cost-restruction and portfolio measures that we are planning, as well as give you a new outlook for the current fiscal year 2025-2026 and an update on our mid-term targets. With that, I'll hand it over to Andreas Pescher, our CEO, and then afterwards, your assistant, our CFO, will take the financial questions. Great. Thank you, Sebastian. Well, good morning, the analysts and the investors. Well, welcome to the six-month 2526 of CallSize Meditech AG. Just as I will walk you through the quarterly overview and financial results. After that, we'll dive deeper and share more details about our ProfitUp program. And at the end, we'll present our guidance for fiscal year 2526 and our midterm outlook. And of course, following the presentation, we'll be happy to take your questions. So let me start with an overview of our six months' performance. Multicutter short, top line, and earnings in the second quarter still remained weak. This weakness was primarily driven by currency headwinds and an unfavorable product mix with weaker sales of intraocular lenses in China. Order entry in six months amounted to 1.038 million or billion euros representing a 5.2% decline adjusted for currency declined by 2.3%. We achieved solid order growth in the EMEA region while demand in ...